Notice of Intent to Publish a Funding Opportunity Announcement for Single Source for Continuation of the Integrated Islet Distribution Program (UC4)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 17, 2026
Can you apply?
This grant is for institutions with expertise in human islet distribution, live cell biology, and diabetes research. The Beckman Research Institute/City of Hope is the single-source awardee, but the Notice of Intent indicates future solicitation for collaborative applications. Organizations with coordinating center capabilities and islet biology expertise are encouraged to develop partnerships. Investigators should begin building collaborations in preparation for the upcoming formal NOFO.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- May 12, 2025 Applications open
- Sep 25, 2025 Application deadline
- Jul 1, 2026 Award announced
- Jul 1, 2026 Project start
Program description
The NIDDK, intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research on { distributing human islets and is announcing its intent to issue a single source cooperative agreement award to Beckman Research Institute/City of Hope for the currently funded Integrated Islet Distribution Program (IIDP) to renew the program and maintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research. The IIDP facilitates the distribution of human islets to biomedical researchers by establishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. The program manages an application process to establish investigator eligibility to receive islet shipments, informs investigators of islet availability, manages a cost recovery system through fees collected from islet recipients, and oversees standardized phenotypic and genotypic analyses of islet preparations distributed throughout the IIDP network. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapies for the prevention and treatment of diabetes}. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the {U24 Resource-Related Research Projects—Cooperative Agreements} activity code. Investigators with expertise and insights into this area of {live cell distribution and human islet biology} are encouraged to begin to consider applying for this new NOFO. In addition, collaborative investigations combining expertise in {coordinating center administration and islet biology} will be encouraged and these investigators should also begin considering applying for this application.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (Application for Federal Assistance)
- Project Narrative
- Budget and Budget Justification
- Biosketch of Key Personnel
- Facilities and Administrative Costs Justification
- Letters of Support from Partner Institutions
Program contact
- 👤 Thomas L Eggerman MD, PhD
- 📧 eggermant@nih.gov
- 📞 301-594-8814
Funding track record
Recent awards under CFDA 93.847 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$438,527,853
-
$200,221,259
-
$152,979,352
-
$112,529,392
-
$66,521,567
-
$45,186,589
-
$39,699,167
-
$37,490,770
-
$34,242,949
-
$31,624,784
Top States by Funding
- WA 3 awards $492.3M
- NC 4 awards $291.6M
- FL 2 awards $184.1M
- MA 6 awards $168.4M
- PA 6 awards $168.1M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.847). How funding has trended year over year.
| 2024 | $1,971,472,000 | |
| 2025 | $2,043,166,000 | |
| 2026 est. | $111,289,000 |
FAQ
What is the Integrated Islet Distribution Program?
IIDP distributes human islets to biomedical researchers and manages an investigator eligibility process, cost recovery system, and phenotypic analyses. It supports diabetes research across a network of islet isolation facilities.
When will applications be accepted?
This is a Notice of Intent. A formal Notice of Funding Opportunity will be published later. Potential applicants should begin developing collaborations now.
Who should apply?
Institutions with expertise in human islet distribution, live cell biology, diabetes research, and coordinating center administration are encouraged to develop collaborative applications.
What is the funding amount?
The total funding pool is $3,300,000 for the continuation of the IIDP program.
Is cost sharing required?
No cost sharing is required for this cooperative agreement award.
💡 Tips for applicants
- Begin developing meaningful collaborations and partnerships now. The Notice is being issued to allow time for investigators to identify potential partners and prepare responsive applications.
- Emphasize expertise in human islet biology and live cell distribution. These are core competencies the program is seeking.
- Highlight coordinating center administration capabilities if your institution plans to lead consortium efforts. Collaborative investigations combining these skills will be encouraged.
- Establish partnerships with qualified islet isolation facilities. The program functions through a network of such partnerships.
- Prepare documentation of your research infrastructure and experience with biospecimen distribution or resource management. This demonstrates capacity to support the IIDP mission.
⚠️ Common mistakes
Applications failing to demonstrate prior experience with human islet handling, cell biology research, or resource distribution infrastructure are unlikely to be competitive. Proposals lacking clear partnerships with qualified islet isolation facilities or coordinating center capacity will be at a disadvantage. Investigators unfamiliar with the cost recovery model and standardized phenotypic/genotypic analysis requirements may underestimate administrative demands.
Similar grants
- OPEN Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed) — National Institutes of Health
- OPEN Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed) — National Institutes of Health
- CLOSED Single Source for Establishing Pilot/Opportunity program for AI Models to Accelerate Diabetes Research (U24- Clinical Trials not allowed) — National Institutes of Health
- CLOSED Notice of Intent to Publish a Funding Opportunity Announcement for Single Source for Continuation of the Environmental Determinants of Diabetes in The Young Study (TEDDY) Data Coordinating Center (U01 — National Institutes of Health
- OPEN Diabetes Research Centers (P30 Clinical Trial Optional) — National Institutes of Health